arrived and was infused after mixing with 2.5cc of 1000 u/ml heparin. The solution 
was frequently agitated and infused at a rate of 2.5 ml/min (25 ml total;10 minute 
infusion period). The rest of the cell infusate arrived and were infused in the same 
manner. B206 was under anesthesia for the same length of time as for the original 
operation. 
Table 4. Blood Chemistries and Hematologies From the First baboon Experiment. 
Normal 
Data From Time Points 
Controls 
8-13 
8-20 
8-22 
8-23 
8-26 
8-29 
9 - 5 
Chemistry 
Glucose 
50-129 
77 
75 
109 
1 05 
1 09 
65 
87 
Creatinine 
0.8-1 .4 
1 .3 
1.5 
1 .4 
1 .3 
1 .09 
1 .44 
1 .64 
BUN 
9-25 
1 4 
1 6 
8 
8 
1 4 
1 0 
1 9 
Cholesterol 
68-232 
85 
80 
82 
76 
74 
85 
87 
Triglycerides21-75 
69 
37 
49 
79 
65 
T. Protein 
5. 8-7. 8 
6.4 
6.6 
6.5 
6.1 
6.4 
7.51 
7.2 
Albumin 
2. 9-4. 2 
4.7 
4.4 
4.0 
4.0 
4.2 
4.5 
4.91 
Globulin 
2. 4-4. 4 
1 .75 
2.1 
2.6 
2.2 
2.2 
3.0 
2.29 
T. Bilirubin 
0.3-0. 7 
0.19 
0.16 
0.33 
0.31 
0.1 
0.2 
0.07 
Calcium 
8. 0-9. 6 
9.9 
9.9 
9.1 
9.1 
9.2 
10.1 
10.6 
Phosphorus 
5.8 
7.4 
7.0 
6.3 
6.2 
8.1 
8.2 
SOOT 
1 6-39 
62 
139 
47 
67 
53 
41 
31 
SGFT 
12-81 
57 
141 
109 
1 1 8 
66 
60 
33 
LDH 
99-488 
308 
550 
240 
214 
227 
71 1 
149 
Alk.Phos. 
1 54-1 1 05 
455 
51 1 
428 
389 
340 
559 
454 
GGTP 
28 
29 
27 
26 
24 
26 
28 
Sodium 
1 43-158 
1 44 
1 49 
141 
1 42 
147 
1 44 
1 42 
Potassium 
3. 2-4. 3 
4.2 
4.1 
4.0 
3.8 
4.0 
4.0 
3.5 
Chloride 
1 04-1 1 8 
106 
97 
96 
98 
9 9 
1 05 
1 08 
CPK 
742 
2877 
667 
975 
93 
473 
Hematology 
HGB 
8.7-13.9 
14.0 
13.4 
13.9 
13.3 
12.2 
13.4 
HCT 
31-43 
42 
WBC 
5.9-20.8 
4.6 
5.9 
5.2 
4.1 
3.7 
4.2 
4.7 
segs% 
22-85 
68 
74 
52 
34 
28 
43 
34 
lymphs% 
12-75 
28 
1 8 
4 1 
52 
66 
48 
56 
eos% 
0-5 
0 
1 
0 
5 
3 
5 
2 
baso% 
0-1 
0 
0 
1 
2 
2 
0 
mono% 
0-4 
4 
7 
6 
7 
3 
2 
8 
PLT 
205-451 
354 
351 
483 
III. Experimental Design 
A. Overall Summary 
We propose to perform ex vivo gene therapy on three patients with homozygous FH. A 
group of patients with advanced CAD who have a poor prognosis will be considered in these 
initial experiments. This treatment will be considered an adjunct to more traditional therapies 
which will be resumed 6 weeks after the gene therapy. Prognosis will be determined during a 
[168] 
Recombinant DNA Research, Volume 15 
